Orexin-A
Hypocretin-1 · HCRT-1 · orexin A
Endogenous 33-aa wake peptide (hypocretin-1). Limitless-style nasal SKU. Orexin-receptor agonists (not this peptide) are the actual narcolepsy-drug story. A gray-market vial of orexin-A is not TAK-861, not pitolisant, and not a substitute for diagnosed narcolepsy care. Blood-brain delivery of the native peptide is the hard problem the drugs were built to avoid.
Quick answer
What it is: Endogenous 33-aa wake peptide (hypocretin-1).
Typical research dose: Intranasal vendor ranges only - not a narcolepsy prescription
Research summary, not medical advice.
Use-case scores
- Cognition2.5/10
Compound card
- Sequence
- 33-aa hypocretin-1
- Class
- Endogenous wake peptide (not TAK-861)
- Formula
- 33-aa hypocretin-1
- Status
- Not FDA-approved · research use
How it works
Orexin-A (hypocretin-1) is the endogenous 33-aa wake peptide at OX1R/OX2R. Narcolepsy type 1 is orexin-neuron loss. The approved/near-approved drug story is small-molecule OX2R agonists - not gray-market native peptide.
Native peptide BBB and PK are why medicinal chemistry did not ship a nasal research vial as standard of care. This leaf is identity for a Limitless-style SKU plus a refusal to dress it as narcolepsy treatment.
Source: Discovery PMID: 9419374; clinical narcolepsy care is not this SKU
Not a narcolepsy prescription
Orexin-A in a research vial is not TAK-861, not pitolisant, not modafinil. Do not delay sleep-medicine care.
Research Use Cases
- ✓Catalog identity: Low
Dosing
| Phase | Dose | Frequency | Notes |
|---|---|---|---|
| Human disease care | Not this SKU | n/a | Use approved/standard narcolepsy therapies with a clinician. |
| Research nasal | Vendor ranges only | Vendor | Not a label. |
Administration
Timeline
Who it is for
Catalog identity
LowListed because people search hypocretin-1 / orexin-A nasal. Not an endorsement.
Reconstitution
Safety & Considerations
Wake peptides can disrupt sleep. Unknown purity on research SKUs. Not a substitute for sleep-disorder diagnosis or treatment.
Regulatory & Legal Status
Native hypocretin-1. Not an approved narcolepsy agonist. Gray-market nasal is not a prescription
Not currently on the WADA 2026 Prohibited List. Policies may change - verify before competition.
Research Chemical
US Compounding: Not eligible / not available
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Limits of current evidence
- Native peptide BBB/PK is why medicinal chemistry went small-molecule.
- This site will not treat narcolepsy from a peptide page.
Verdict
Orexin-A is hypocretin-1. Narcolepsy type 1 is orexin-neuron loss. A research vial is not the small-molecule OX2R agonist pipeline. Do not delay sleep-medicine care.
Interactions & Contraindications
Wake peptides can disrupt sleep. Unknown purity on research SKUs. Not a substitute for sleep-disorder diagnosis or treatment.
Orexin-A vs. DSIP
Canonical comparison: Orexin-A vs DSIP
| Attribute | Orexin-A | DSIP |
|---|---|---|
| Job | Endogenous wake peptide (OX1R/OX2R) | Delta-sleep-inducing peptide (research) |
| Narcolepsy drugs | Native peptide is not the approved agonist class | Not a narcolepsy drug either |
| SKU | Nasal research | Research peptide |
Verdict: Orexin-A is a wake peptide. DSIP is a sleep-research peptide. Opposite jobs. Neither is a prescription sleep-disorder therapy from a research vial.
Frequently Asked Questions
Will this treat narcolepsy?▼
Prescription options: compare licensed telehealth providers
Some peptide therapies are available only by prescription after a consult with a licensed clinician.